Pharma Articles
Renowned pharmaceutical firm executives and other experts from around the world write articles on current topics in the industry. The section of articles on the pharmaceutical sector focuses on contemporary and expanding challenges in fields such as pharmaceutical R&D, drug discovery, clinical trials, pharmaceutical production, biopharmaceuticals, and information technology.
Beyond GLP-1: Emerging Biologic Therapies Reshaping Chronic Disease Care
For most of the last decade the strategic argument inside pharmaceutical boardrooms about chronic disease was an argument about incrementalism Franchises were defended with line extensions device improvements and marginal tolerability gains Then a peptide class built for glycaemic control turned int...
Strategic Investments in Continuous Manufacturing for Competitive Advantage
Continuous manufacturing has been discussed in American pharmaceutical boardrooms for well over a decade usually as a promising technology that someone else would prove first That posture is no longer defensible Commercial approvals covering continuously manufactured products now exist the regulator...
Continuous Manufacturing: The New Standard for Agile Pharma Production
American pharmaceutical executives have spent the past several years managing consequences that trace back to a production model designed for a different century Shortages concentrated in older
Digital Transformation in Pharma: Integrating AI & Automation Technologies
Every pharmaceutical boardroom now has an artificial intelligence slide Far fewer have an artificial intelligence balance sheet The past three years produced a remarkable volume of experimentation across the industry generative models proposing molecules feasibility engines redesigning trial protoc...
AI-Powered Clinical Trials: Accelerating Study Design and Execution
For more than a decade the industrys capital and attention have flowed toward the front of the pipeline Target identification generative chemistry and structural prediction have all been genuinely transformed Yet the median interval from firstinhuman dosing to approval has barely moved The reason is...
Foundation Models in Drug Discovery: The Next Frontier of Pharmaceutical Research
For most of the past decade computational drug discovery ran on bespoke machinery One model per assay One model per target class One model per endpoint Each required its own labeled dataset its own validation exercise its own maintenance schedule and its own team of people who understood what it did...
Financing Biopharma Innovation in a Constrained Capital Market
Every biopharmaceutical enterprise runs two businesses simultaneously One develops medicines The other raises and allocates the capital that makes development possible In favorable markets the second business is largely invisible to the first and executive attention concentrates where it belongs on...
Winning the Biosimilars Market: Strategic Imperatives for Sustainable Growth
Ask a biosimilars executive how the US market feels right now and the metaphor arrives before the sentence finishes a bloodbath It is not hyperbole Within twelve months of the first adalimumab biosimilar reaching American patients in January the net price per prescription for the reference product...
Why Great Science Still Fails at the Regulatory Finish Line
Every drug development organization is built to answer one question does the molecule work Billions of dollars decades of institutional memory and the entire architecture of the modern RD function are oriented toward that single proof
Inside the Approval Timeline: Where Programs Really Lose Months
Ask a development team why their program slipped two quarters and youll usually hear about the obvious culprits a clinical hold an unexpected safety signal a manufacturing deviation These are the losses that get postmortems and steeringcommittee attention But they are not in aggregate where most pro...
